What is cruise and blast and how does Oxymetholone fit into this protocol?

Cruise and blast is a long-term androgen management strategy where practitioners alternate high-dose blast phases with lower-dose cruise phases instead of cycling fully off. Oxymetholone is used exclusively during the blast phase to rapidly elevate erythropoietic output and nitrogen retention. It is not continued through the cruise phase due to its hepatic load, making it a targeted blast-phase tool rather than a year-round compound.

How long should the blast phase with Oxymetholone typically last within a cruise and blast structure?

Most harm-reduction-informed practitioners limit Oxymetholone's blast-phase role to four to six weeks to manage cumulative hepatic enzyme elevation. Within a cruise-and-blast calendar, this means one to two Oxymetholone-assisted blasts per year are realistic given the recovery interval required between exposures. ALT and AST values should return to baseline before Oxymetholone is reintroduced in a subsequent blast block.

When do you switch from an Oxymetholone blast back to a cruise phase?

The switch is triggered by either reaching the planned blast duration limit or crossing a pre-set biomarker threshold — typically ALT or AST rising beyond three times the upper reference limit, or haematocrit exceeding 52–54 percent. At that point Oxymetholone is discontinued and the practitioner drops back to the cruise-phase androgen dose. Monitoring should continue for at least two weeks after discontinuation to confirm enzyme normalisation.

Can the Oxypolon 25mg tablets be split to achieve doses below 25mg during the cruise-phase entry ramp?

Tablet splitting is not recommended for precision dose management because mechanical division can produce unequal API distribution across the two halves. The 25 mg unit is already the smallest available format for Oxymetholone and represents a practical lower bound for active dosing within a blast context. For sub-25 mg intentions, Oxymetholone is generally discontinued entirely and the protocol reverts to the cruise-phase base compound.

How many tablets does the 100-tablet Oxypolon pack cover for a standard blast phase?

At 50 mg per day (two tablets daily), the 100-tablet pack covers a 50-day supply — sufficient for a full six-week blast block with a two-week entry ramp at 25 mg per day. At a conservative 25 mg per day during the escalation period, the same pack supports a structured induction before peak blast exposure without requiring an additional order mid-cycle. (2) angle_used

Established Brand

Knoll Pharmaceuticals

Oxypolon 25mg/tab 100 Tabletten by Knoll Pharmaceuticals

Name: Oxypolon 25mg/tab 100 Tablets by Knoll Pharmaceuticals
Brand: Knoll Pharmaceuticals
SKU: ORA-OXYM-KNO-012
Price: 65.00 EUR
Availability: InStock

Oxypolon by Knoll Pharmaceuticals delivers Oxymetholone at 25 mg per tablet across a 100-tablet pack, purpose-built for athletes who structure their training year around alternating blast and cruise phases rather than single, time-limited cycles. The 25 mg tablet format provides the granular dose control that cruise-to-blast transitions demand — allowing practitioners to escalate or taper total daily milligrams in precise increments without cutting tablets. HPLC content assay at the lot level and GMP-compliant tablet compression are applied to every Oxypolon batch; traceability of API specification is maintained from raw material intake through finished blister release.

€65.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers rapid blast-phase erythropoietic stimulus within the first two weeks of elevated-dose administration.
25 mg tablet unit enables single-increment step-ups at each cruise-to-blast transition boundary.
100-tablet pack covers a full six-week blast block plus a two-week entry ramp without mid-cycle reordering.
HPLC-verified per-tablet content ensures dose accuracy across a long multi-phase protocol horizon.
GMP-compliant tablet compression maintains API uniformity required for biomarker-guided phase management.
LAL endotoxin screening on incoming raw API adds a quality checkpoint beyond standard tablet-format testing.

Phase	Daily Oxymetholone Dose	Note
Cruise (base androgen only)	0 mg — Oxypolon not used	Maintain cruise-phase injectable or oral androgen; Oxymetholone is withheld entirely during this interval.
Blast Entry Ramp (Weeks 1–2)	25 mg/day (1 tablet)	Assess ALT, AST, haematocrit at the end of Week 2 before advancing to full blast dose.
Full Blast Peak (Weeks 3–6)	50–75 mg/day (2–3 tablets)	Hold peak dose only if Week 2 biomarkers remain within acceptable range; limit this phase to four weeks.
Blast Exit / Return to Cruise	Taper to 25 mg/day for 3–5 days, then discontinue	Recheck liver enzymes two weeks after Oxymetholone cessation before planning the next blast block.

Key takeaways

Reserve Oxypolon exclusively for the blast phase, never the cruise interval.
Escalate in 25 mg single-tablet increments at each phase boundary.
Monitor ALT, AST, and haematocrit before advancing to peak blast dose.
Limit each Oxymetholone blast block to six weeks maximum per HPLC-informed protocols.
Use the 100-tablet count to plan a full escalation-to-peak blast sequence without reordering.

Oxymetholone in a Blast and Cruise Framework

Oxypolon by Knoll Pharmaceuticals is a 25 mg oral Oxymetholone tablet designed to function as the blast-phase intensifier within a long-term cruise-and-blast training protocol, where periods of supraphysiological androgen exposure (blasts) alternate with lower-dose maintenance intervals (cruises). Cruise-and-blast differs structurally from conventional cycling: there is no full off-cycle, and the practitioner manages total androgen load continuously across calendar quarters rather than in isolated blocks. Oxymetholone serves the blast phase specifically because its erythropoietic and nitrogen-retention effects are rapid-onset — meaningful changes in red blood cell mass and intramuscular nitrogen accumulation are measurable within the first two weeks of elevated-dose administration based on haematological panel data.

Dose Precision During Phase Transitions

Transitioning from cruise to blast requires a stepped dose escalation rather than an immediate jump to peak exposure. The 25 mg tablet unit allows practitioners to move from a cruise-phase baseline of 25 mg per day to 50 mg, 75 mg, or 100 mg daily in single-tablet increments — a level of precision that 50 mg tablets cannot deliver without splitting. Compared to a 50 mg fixed-unit format, the 25 mg tablet reduces titration error at phase boundaries by eliminating the need for mechanical tablet division, which HPLC dissolution profiling has shown introduces API distribution variability. Each escalation step can be held for a defined period (typically one to two weeks) while ALT, AST, and haematocrit are assessed before proceeding to full blast-phase dosing.

Pack Size and Long-Horizon Planning

The 100-tablet count directly supports multi-phase cruise-and-blast planning. A practitioner running an eight-week blast at 50 mg per day consumes 2,800 mg total; 100 tablets at 25 mg each provide exactly that 2,500 mg core blast block, covering a full escalation-to-peak sequence with a small buffer for the entry-ramp period. Knoll Pharmaceuticals subjects each Oxypolon lot to HPLC-based per-tablet content verification and LAL endotoxin screening on the incoming API, ensuring that the dose consistency required for biomarker-guided phase management is maintained across the full 100-tablet run.

Usage

Establish your cruise-phase baseline first: confirm that your base androgen (typically a long-ester injectable) is at a stable, well-tolerated maintenance dose before introducing Oxypolon.
Obtain a pre-blast blood panel — ALT, AST, total bilirubin, haematocrit, and haemoglobin — to establish individual reference values before your first tablet.
Begin the entry ramp at one tablet (25 mg) per day, taken with a moderate-fat meal to support absorption without delaying gastric transit excessively.
At the end of Week 2, retest ALT, AST, and haematocrit; advance to two tablets (50 mg) per day only if values remain within your pre-set safety thresholds.
Maintain peak blast dose for no longer than four consecutive weeks; log daily energy, strength performance, and any subjective side effects at each training session to detect early signs of overexposure.
Execute the blast exit by stepping down to one tablet (25 mg) for three to five days before full discontinuation, then return to your cruise-phase androgen protocol only, retesting liver enzymes two weeks later.

Warnings

Contraindications: Oxypolon is contraindicated in individuals with pre-existing hepatic impairment, elevated baseline ALT or AST, diagnosed or suspected prostate or breast carcinoma, polycythaemia, or a history of hypercalcaemia. Women of childbearing potential should not use this compound. Individuals on anticoagulant therapy require heightened caution as Oxymetholone potentiates the activity of oral anticoagulants.

Side Effects: Common adverse effects include fluid retention, increased blood pressure, and hepatic enzyme elevation (ALT, AST). Erythropoietic stimulation may drive haematocrit into ranges associated with increased blood viscosity. Androgenic effects such as scalp hair thinning and acne are possible. Cholestatic jaundice and peliosis hepatis have been documented in the medical literature at doses and durations exceeding harm-reduction guidelines.

Monitoring: Full hepatic panel (ALT, AST, total bilirubin, GGT) is recommended at baseline, at the end of the entry ramp (Week 2), at peak blast midpoint (Week 4), and two weeks post-cessation. Haematocrit should be tracked alongside hepatic markers; values approaching 54 percent warrant immediate dose reduction or discontinuation. Blood pressure should be self-monitored at least three times per week throughout the blast phase.

PCT: Because cruise-and-blast practitioners do not complete a full off-cycle, traditional post-cycle therapy is replaced by a return to the established cruise-phase androgen protocol. Endogenous testosterone recovery is not a goal within a cruise-and-blast framework. Hepatoprotective agents (e.g. TUDCA, NAC) are commonly co-administered throughout the Oxymetholone blast phase to support bile acid clearance and mitigate oxidative hepatic stress.

Frequently asked questions

What is cruise and blast and how does Oxymetholone fit into this protocol?: Cruise and blast is a long-term androgen management strategy where practitioners alternate high-dose blast phases with lower-dose cruise phases instead of cycling fully off. Oxymetholone is used exclusively during the blast phase to rapidly elevate erythropoietic output and nitrogen retention. It is not continued through the cruise phase due to its hepatic load, making it a targeted blast-phase tool rather than a year-round compound.
How long should the blast phase with Oxymetholone typically last within a cruise and blast structure?: Most harm-reduction-informed practitioners limit Oxymetholone's blast-phase role to four to six weeks to manage cumulative hepatic enzyme elevation. Within a cruise-and-blast calendar, this means one to two Oxymetholone-assisted blasts per year are realistic given the recovery interval required between exposures. ALT and AST values should return to baseline before Oxymetholone is reintroduced in a subsequent blast block.
When do you switch from an Oxymetholone blast back to a cruise phase?: The switch is triggered by either reaching the planned blast duration limit or crossing a pre-set biomarker threshold — typically ALT or AST rising beyond three times the upper reference limit, or haematocrit exceeding 52–54 percent. At that point Oxymetholone is discontinued and the practitioner drops back to the cruise-phase androgen dose. Monitoring should continue for at least two weeks after discontinuation to confirm enzyme normalisation.
Can the Oxypolon 25mg tablets be split to achieve doses below 25mg during the cruise-phase entry ramp?: Tablet splitting is not recommended for precision dose management because mechanical division can produce unequal API distribution across the two halves. The 25 mg unit is already the smallest available format for Oxymetholone and represents a practical lower bound for active dosing within a blast context. For sub-25 mg intentions, Oxymetholone is generally discontinued entirely and the protocol reverts to the cruise-phase base compound.
How many tablets does the 100-tablet Oxypolon pack cover for a standard blast phase?: At 50 mg per day (two tablets daily), the 100-tablet pack covers a 50-day supply — sufficient for a full six-week blast block with a two-week entry ramp at 25 mg per day. At a conservative 25 mg per day during the escalation period, the same pack supports a structured induction before peak blast exposure without requiring an additional order mid-cycle. (2) angle_used

Manufacturer

Knoll Pharmaceuticals distinguishes its customer-facing infrastructure through responsive post-purchase support: purchasers of Oxypolon can access lot-specific quality documentation — including HPLC content assay results and raw API endotoxin screening records — through direct inquiry to the Knoll support channel, with batch traceability maintained from API intake through finished blister release. This transparency-first service model means questions about tablet specification, storage requirements, or batch identity receive documentation-backed responses rather than generic replies. For cruise-and-blast practitioners whose protocols are built on consistent per-tablet API delivery across multi-month timelines, Knoll's willingness to provide lot-level traceability data on request represents a practical service advantage over suppliers operating without accessible quality records.

Product details

Brand	Knoll Pharmaceuticals
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Oxypolon, Knoll Pharmaceuticals Anadrol
Strength	25 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-OXYM-KNO-012

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00